Robin Tuohy's testimony at CEPAC on Treatment Options for Relapsed and Refractory Myeloma
On May 26, 2016, the International Myeloma Foundation’sSenior Director of Support Groups and spouse of Michael Tuohy, a sixteen-year myeloma survivor, testified at the Comparative Effectiveness Public Advisory Council’s Public Meeting (CEPAC) on Treatment Options for Relapsed and Refractory Myeloma. In her compelling testimony, Robin shared how her husband Michael’s survival as a myeloma patient may not have been possible without access to a clinical trial, an [and] oral therapy regimen, he has been on for the past eleven years. She pointed out, “Today we are able to treat myeloma in seque...
Source: International Myeloma Foundation - June 10, 2016 Category: Hematology Source Type: news
Pre-EHA Chinese Hematologist Round Table
IMF in cooperation with Xian-Janssen (XJP) is hosting the Pre-EHA Chinese Hematologists Round Table at the Hotel Scandic Copenhagen in Copenhagen, Denmark. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 10, 2016 Category: Hematology Source Type: news
The IMWG Conference Series "Making Sense of Treatment" < br >
7th IMWG Summit | June 9, 2016
< p > Drs. Brian GM Durie, Joseph Mikhael,Paul Richardson < span style="line-height: 1.6em;" > , and Maria Victoria Mateos discusses the latest news and trends in the treatment of Multiple Myeloma. < /span > < /p > (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 9, 2016 Category: Hematology Source Type: news
The IMWG Conference Series "Making Sense of Treatment"
7th IMWG Summit | June 9, 2016
Drs. Brian GM Durie, Joseph Mikhael,Paul Richardson, and Maria Victoria Mateos discusses the latest news and trends in the treatment of Multiple Myeloma. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 9, 2016 Category: Hematology Source Type: news
Living Well with Myeloma: < br >
What you Need to Know to Overcome Side Effects from Novel Therapies
< p > < strong > Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN < /strong > < br / >
Cleveland Clinic Taussig Cancer Institute < br / >
Multiple Myeloma Program < br / >
Cleveland, OH & nbsp; < /p > < p > < strong > Kevin Brigle, PhD, NP < /strong > < br / >
VCUHS Massey Cancer Center < br / >
Richmond, VA & nbsp; < /p > (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 5, 2016 Category: Hematology Source Type: news
Living Well with Myeloma:
What you Need to Know to Overcome Side Effects from Novel Therapies
Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN
Cleveland Clinic Taussig Cancer Institute
Multiple Myeloma Program
Cleveland, OH
Kevin Brigle, PhD, NP
VCUHS Massey Cancer Center
Richmond, VA (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 5, 2016 Category: Hematology Source Type: news
International Myeloma Foundation Brings Together 100 of the World's
Top Myeloma Experts June 7-9, 2016 in Copenhagen for 7th Annual Summit
< p > Addressing Rising Cost of Myeloma Treatments to Be a Key Focus < /p > (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 2, 2016 Category: Hematology Source Type: news
International Myeloma Foundation Brings Together 100 of the World's
Top Myeloma Experts June 7-9, 2016 in Copenhagen for 7th Annual Summit
Addressing Rising Cost of Myeloma Treatments to Be a Key Focus (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 2, 2016 Category: Hematology Source Type: news
Pierre S. Sayad Joins IMF as Senior Vice President, Global Medical Affairs and Strategic Partnerships
(Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 1, 2016 Category: Hematology Source Type: news
International Myeloma Foundation Honors Dr. S. Vincent Rajkumar
With the 2016 Robert A. Kyle Lifetime Achievement Award
< p > Given in Recognition of Significant Contributions to Myeloma Research and Patient Care < /p > (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 31, 2016 Category: Hematology Source Type: news
International Myeloma Foundation Honors Dr. S. Vincent Rajkumar
With the 2016 Robert A. Kyle Lifetime Achievement Award
Given in Recognition of Significant Contributions to Myeloma Research and Patient Care (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 31, 2016 Category: Hematology Source Type: news
ASCO 2016: More Excitement About Daratumumab (Darzalex & #174;) and Tremendous Interest in Value and Costs
As usual, far fewer myeloma-related abstracts will be presented at next month's annual meeting of the American Society of Clinical Oncology (ASCO) than are presented at the annual meeting of the American Society of Hematology (ASH) each December. But, writes IMF Chairman Dr. Brian Durie in his blog this week, the results of the Phase III CASTOR study have created some excitement, and the subjects of “cost” and “value” in cancer treatment are definitely in the air! To read Dr. Durie's blog, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 27, 2016 Category: Hematology Source Type: news
Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards
The Brian D. Novis Research Awards honor the IMF's founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin-derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 1, 2016 is the deadline for applications. For more information and grant applications, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 27, 2016 Category: Hematology Source Type: news
ASCO 2016: More Excitement About Daratumumab (Darzalex®) and Tremendous Interest in Value and Costs
As usual, far fewer myeloma-related abstracts will be presented at next month's annual meeting of the American Society of Clinical Oncology (ASCO) than are presented at the annual meeting of the American Society of Hematology (ASH) each December. But, writes IMF Chairman Dr. Brian Durie in his blog this week, the results of the Phase III CASTOR study have created some excitement, and the subjects of “cost” and “value” in cancer treatment are definitely in the air! To read Dr. Durie's blog, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 27, 2016 Category: Hematology Source Type: news
International Myeloma Foundation (IMF) Says Controversial Drug Cost Report Could Limit Patient Access to Optimal Treatment
IMF Raises Red Flags in Advance of May 26 Hearing, Offers Alternate Approach (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 24, 2016 Category: Hematology Source Type: news
